Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)
Clinical trial NCT05398848 · COMPLETED
Trial details
- NCT number
- NCT05398848
- Sponsor
- Jiangsu Rec-Biotechnology Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-31
- Primary completion
- 2023-09-04
- Enrollment
- 7623
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.